Fantasy Football - Footballguys Forums
This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!
Stock Thread (28 Viewers)
- Thread starter St. Louis Bob
- Start date
djmich
Footballguy
Did you get back in bigger yesterday. I'm tired of my good buddy Chet having to drag you along.
Jayrok
Footballguy
This type of chatter of approval in Mexico is another reason, perhaps, why yesterday was the selected date of the attack. Shorts may be running out of time and want to squeeze this as much as possible before approval, whether from the FDA or other countries.
The Citron article was filled with old accusations and issues that have been addressed and answered. They know this but they also know there are lots of new investors that weren't around in April/May when the last major attack occurred. New investors were understandably shocked yesterday. We all were. Hopefully they'll come back to the table.
Wish they'd get up-listed and bring in major investor money to force shorts to seek another OTC biotech company to terrorize.
Jayrok
Footballguy
Saw this elsewhere: "First, take this to the bank, don't use stop orders. That info is available for those hostile to your success to use it against you."
They knew the stop orders would help in their attack and is probably why it fell as far as it did.
caustic
Footballguy
Covid-19 vaccine from Pfizer and BioNTech shows positive results
Futures jumped a bit on the news, but this seems to be far from a finished product:
An experimental Covid-19 vaccine being developed by the drug giant Pfizer and the biotech firm BioNTech spurred immune responses in healthy patients, but also caused fever and other side effects, especially at higher doses.
The first clinical data on the vaccine were disclosed Wednesday in a paper released on MedRXiv, a preprint server, meaning it has not yet been peer-reviewed or published in a journal.
The Pfizer study randomly assigned 45 patients to get one of three doses of the vaccine or placebo. Twelve receive a 10 microgram dose, 12 a 30 μg dose, 12 a 100 μg dose, and nine a placebo. The 100 μg dose caused fevers in half of patients; a second dose was not given at that level.
Following a second injection three weeks later of the other doses, 8.3% of the participants in the 10 μg group and 75% of those in the 30 μg group developed fevers. More than 50% of the patients who received one of those doses reported some kind of adverse event, including fever and sleep disturbances. None of these side effects was deemed serious, meaning they did not result in hospitalization or disability and were not life-threatening.
The vaccine generated antibodies against SARS-CoV-2, the virus that causes Covid-19, and some of these antibodies were neutralizing, meaning that they appear to prevent the virus from functioning. Levels of neutralizing antibodies were 1.8- to 2.8-times the level of that in the recovered patients.
It’s not certain that higher antibody levels will lead to immunity to the virus. To prove that, Pfizer will need to conduct large studies that aim to prove that people who have received the vaccine are at least 50% less likely to become infected. Those studies are expected to begin this summer, mostly in the United States. Pfizer is testing four different versions of the vaccine, but only one will advance to larger studies.
The current study did not include pregnant women, and no other information on the ethnic diversity of participants was noted, although the paper does say that future studies will need to include a more diverse group.
The second dose, a booster shot, was required for immunity. The patients who received the single 100 μg dose had lower antibody levels than those who received two shots of the lower doses.
Fourteen Covid-19 vaccines are currently in human trials, according to the Milken Institute, including entrants from Inovio, CanSino, AstraZeneca, and Moderna. More are expected to start soon, including entrants from Merck, Johnson & Johnson, and Sanofi. In total, 178 vaccines are in various stages of development.
The Pfizer/BioNTech vaccine, like the Moderna vaccine, is based on a technology called messenger RNA, which uses a key genetic messenger found in cells to create protein that the immune system then learns to attack. Moderna has not yet published data on its vaccine but is expected to do so soon.
Futures jumped a bit on the news, but this seems to be far from a finished product:
An experimental Covid-19 vaccine being developed by the drug giant Pfizer and the biotech firm BioNTech spurred immune responses in healthy patients, but also caused fever and other side effects, especially at higher doses.
The first clinical data on the vaccine were disclosed Wednesday in a paper released on MedRXiv, a preprint server, meaning it has not yet been peer-reviewed or published in a journal.
The Pfizer study randomly assigned 45 patients to get one of three doses of the vaccine or placebo. Twelve receive a 10 microgram dose, 12 a 30 μg dose, 12 a 100 μg dose, and nine a placebo. The 100 μg dose caused fevers in half of patients; a second dose was not given at that level.
Following a second injection three weeks later of the other doses, 8.3% of the participants in the 10 μg group and 75% of those in the 30 μg group developed fevers. More than 50% of the patients who received one of those doses reported some kind of adverse event, including fever and sleep disturbances. None of these side effects was deemed serious, meaning they did not result in hospitalization or disability and were not life-threatening.
The vaccine generated antibodies against SARS-CoV-2, the virus that causes Covid-19, and some of these antibodies were neutralizing, meaning that they appear to prevent the virus from functioning. Levels of neutralizing antibodies were 1.8- to 2.8-times the level of that in the recovered patients.
It’s not certain that higher antibody levels will lead to immunity to the virus. To prove that, Pfizer will need to conduct large studies that aim to prove that people who have received the vaccine are at least 50% less likely to become infected. Those studies are expected to begin this summer, mostly in the United States. Pfizer is testing four different versions of the vaccine, but only one will advance to larger studies.
The current study did not include pregnant women, and no other information on the ethnic diversity of participants was noted, although the paper does say that future studies will need to include a more diverse group.
The second dose, a booster shot, was required for immunity. The patients who received the single 100 μg dose had lower antibody levels than those who received two shots of the lower doses.
Fourteen Covid-19 vaccines are currently in human trials, according to the Milken Institute, including entrants from Inovio, CanSino, AstraZeneca, and Moderna. More are expected to start soon, including entrants from Merck, Johnson & Johnson, and Sanofi. In total, 178 vaccines are in various stages of development.
The Pfizer/BioNTech vaccine, like the Moderna vaccine, is based on a technology called messenger RNA, which uses a key genetic messenger found in cells to create protein that the immune system then learns to attack. Moderna has not yet published data on its vaccine but is expected to do so soon.
sporthenry
Footballguy
Eh, a green open is a good one. I'd imagine vaccine news may put a damper on CYDY but reduced volatility may be a good thing in the near-term. Also, would folks buy in front of NP? I'm not as close to the story but from what I can gather, NP does the same to the stock as Powell does to the S&P when he talks.
djmich
Footballguy
Nugget
Footballguy
sporthenry
Footballguy
https://www.otcshortreport.com/company/CYDY
Here is the short volume yesterday. Says 22mn of the 54 million shares traded were short. No idea how much was covered. But any further covering could cause a spike in the stock so be careful tailing rallies. Wouldn't be surprised if Citron bails today, if they haven't already, if they're going to pull down that piece.
Here is the short volume yesterday. Says 22mn of the 54 million shares traded were short. No idea how much was covered. But any further covering could cause a spike in the stock so be careful tailing rallies. Wouldn't be surprised if Citron bails today, if they haven't already, if they're going to pull down that piece.
I want to comment on the wash rule. The way I read it, if you hold no position on it at end of year, and don't buy back within 30 days in January, it's meaningless and you can buy and sell all day long. It's hard to find it worded like that in the wash rule definition. Correct me if wrong, but since that is what I did in 2000 and claimed all loses, I believe it is correct.
Jayrok
Footballguy
Misleading Headline on CydoDyn (CYDY) Triggers Algo Selling
Timing. Hopefully an up-listing is near making it hard for these types of things to happen going forward. No halts on OTC stocks I guess.
ghostguy123
Footballguy
So the shorters made an absolute killing then?
eaganwildcats
Footballguy
What are the prognostications for what NP discusses on this investor update? My biggest fear, candidly, is there is no specific good news and instead just rambling about all the things that might happen in the "next 2-5 weeks". If not specific news my strong preference would have been for them to just keep quiet and wait for something actual to report.
sporthenry
Footballguy
Sykes seems the biggest scumbag of them all. Come across him on TWTR while searching for CYDY. He's the one who probably started this. Seems like they probably used Left and Citron for their own means. Not that Citron shouldn't have vetted it more.
eaganwildcats
Footballguy
Jayrok
Footballguy
I don't follow them but people are saying there is lots of gloating going on in twitter feeds. I'm sure they did great. Some of the seasoned shorters probably did better than some of their minions. Some of them may still be trying to cover this morning. Which could help raise the SP some.
This happens and the silver lining for investors is that this didn't happen because some is fundamentally wrong with the company. It happened because of fear. The short gang hit the jackpot on this attack because their target price triggered all those stop loss sell orders. This drove the price down as far as it did.
OTOH, it gave us a nice opportunity to pick up some more shares a lot cheaper than it would have on Monday.
I read they did this same attack in March/April on INO (another biotech). Drove the SP down to 2. Today they're trading near $30. So, it survived and is thriving now. Said much of the exact verbiage in the article was used in that attack. Interesting that Citron removed that piece quickly yesterday. Says a lot. But he doesn't care since his money was made.
Jayrok
Footballguy
The article above states the Sykes is the one the tweeted the Citron report to his network of criminals.
This is super important. When I saw the plummet yesterday, my first thought was that the FDA said something bad or a patients on their drug were showing some horrible complication. In those cases, it might be prudent to dump shares. As soon as I learned about the short attack (once again, thanks to chet), it mostly calmed my nerves. Nothing wrong here, in fact it is a sign of a lot of good stuff: a very quick and decisive run up to a fairly round number. Give them credit, they timed the attack perfectly and triggered a bunch of stop loss orders. Don't get me wrong, I think they are lowlifes and this behavior should be regulated against but it was a well-perpetrated heist.
The Ref
Footballguy
I blocked him yesterday. Within 2 minutes of the bottom there was no less than 15 tweets about how his minions bought the bottom and sold $1 later and made a quick $500 and how he is the lord and savior.
General Malaise
Footballguy
How did they get the borrow to short?
The Ref
Footballguy
Moonlight
Footballguy
I'm the other way. Address the raid, assure investors and hopefully provide information regarding what if anything can be done about it. I would think that he would provide an update on the uplisting as part of this.
djmich
Footballguy
This Nader video is going to be so intriguing and potentially telling.
My opinion:
They've been quiet for the past few weeks for a reason. Something is known/happening. Buyout discussions, preliminary results, whatever. Doesn't necessarily have to be good, although the run up is promising.
If Nader is super scripted and much more careful that his typical "interviews" that to me helps confirm something is up.
If discussion about risks or other CYA type language is used (even if mixed in with positives) I'll be concerned.
If that language is not used that to me is a good sign and hopefully whatever else he says would support that.
My opinion:
They've been quiet for the past few weeks for a reason. Something is known/happening. Buyout discussions, preliminary results, whatever. Doesn't necessarily have to be good, although the run up is promising.
If Nader is super scripted and much more careful that his typical "interviews" that to me helps confirm something is up.
If discussion about risks or other CYA type language is used (even if mixed in with positives) I'll be concerned.
If that language is not used that to me is a good sign and hopefully whatever else he says would support that.
adonis
Footballguy
I watched several interviews with him and what I'd love to see less of is a salesman approach to hyping the potential, and more of a focus on results. He used phrasing that reminded me of Donald Trump - something to the effect of "People couldn't believe the positive results they were seeing. It was incredible." Just a lot of hype language. Watched Dr. Patterson's videos too, and I've worked around a lot of research MD's and to be honest his boosterism of the drug made me a little uncomfortable just from previous experience with doctors being more reserved. I suppose it'd be natural if you found a drug that truly worked as well as he says it does, but at the same time I'm not used to seeing such praise heaped onto a drug in this situation. I'd love to rule out what financial incentives he has, or publication incentives, for the success of the drug to be more comfortable with his reviews.
Jayrok
Footballguy
SA author posted a retraction, of sorts. Citron pulls bearish Cytodyn Report
Damage was done but at least Seeking Alpha told him to post a follow-up.
Damage was done but at least Seeking Alpha told him to post a follow-up.
bshell27
Footballguy
They are not going to produce this themselves. A buyout is the only outcome if this drug is truly effective.
Jayrok
Footballguy
Random
Footballguy
Zegras11
Footballguy
djmich
Footballguy
Charlie Harper
Footballguy
adonis
Footballguy
I'd not be opposed. Miss seeing more of the other stock talk, but understandable that the last day's activity took up a lot of discussion in here. Am curious about value other folks see in the broader market now though.
